Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

ICER says AstraZeneca’s new blood pressure med isn’t cost-effective

The drug price watchdog ICER issued a report Thursday concluding that the benefits of AstraZeneca’s new blood pressure pill Baxfendy don’t justify its $10,950 per year price tag. Baxfendy is forecast to be a major ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

Back-to-School at USP

Back-to-School at USP

Brian McNally, PhD, director of global biologics marketing & strategic collaborations at USP provides his insight on building the workforce behind the next generation of medicines.

More from Friday 14 August →